Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H17F2N5O3S |
Molecular Weight | 409.41 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(N)=N[C@@](C)(CS1(=O)=O)C2=CC(NC(=O)C3=CC=C(F)C=N3)=CC=C2F
InChI
InChIKey=YHYKUSGACIYRML-KRWDZBQOSA-N
InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1
Verubecestat (MK 8931) is a potentially first-in-class, potent β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor being developed by Merck. Verubecestat (MK-8931) is a selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of Aβ40, Aβ42, and sAPPβ (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys. Verubecestat was under investigation for the treatment of Alzheimer's disease, prodromal Alzheimer's disease, and amnestic mild cognitive impairment. In November 2013, Merck began the APECS trial in 1,500 participants with prodromal AD, aka mild cognitive impairment due to AD (aMCI). These patients have measurable cognitive deficits and a positive PET scan with the newly FDA-approved amyloid tracer flutemetamol, but are not functionally impaired. APECS compared 12 and 40 mg once-daily doses to placebo; treatment was to last for two years. APECS usef change from baseline on the Clinical Dementia Rating Sum of Boxes (CDR-SB), a continuous measure, as its primary outcome. Secondary outcomes evaluated a range of newer measures, including a cognitive composite, CSF tau, brain imaging of hippocampal volume and amyloid load, and others. This trial was being conducted in more than 90 locations worldwide; it completed enrollment in November 2016 and was expected to complete data collection for its primary outcome in 2019. In February 2018, APECS was discontinued and Merck no longer listed verubecestat in its research pipeline. APECS participants on 40 mg verubecestat scored worse than the placebo group on the CDR-SB and ADAS-Cog13 starting at 13 weeks. The effect was small and did not progress over time. The 12 mg treatment group also performed slightly worse than controls, with the difference reaching significance at scattered time points.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24556009 |
|||
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23412139 |
7.8 nM [Ki] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.alzforum.org/therapeutics/verubecestat
12, 40, or 60 mg/day of Verubecestat (MK 8931) given as once-daily tablets to placebo in people with mild to moderate AD.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
||
|
NCI_THESAURUS |
C1509
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C152868
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
SUB185177
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
1286770-55-5
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
100000170947
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
J1I0P6WT7T
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
Verubecestat
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
DTXSID30102062
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
51352361
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL3301601
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
10028
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
1613380-81-6
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
SUPERSEDED | |||
|
BC-75
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY | |||
|
DB12285
Created by
admin on Sat Dec 16 11:24:32 GMT 2023 , Edited by admin on Sat Dec 16 11:24:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)